What is the best treatment for iodine-refractory thyroid cancer metastases to the iliac bone?

Best Treatment for Iodine-Refractory Thyroid Cancer Metastases to the Iliac Bone

For iodine-refractory differentiated thyroid cancer with iliac bone metastasis, systemic therapy with lenvatinib is the preferred first-line treatment if the disease is clinically progressive or symptomatic, while external beam radiation therapy with BED10 ≥ 40 should be strongly considered for local control of the bone lesion. 1, 2

Systemic Therapy Framework

The 2025 NCCN Guidelines establish that kinase inhibitors are the standard systemic approach for RAI-refractory DTC, with lenvatinib as the preferred intervention based on superior efficacy, safety, and evidence 1. Clinical trials demonstrate that kinase inhibitors achieve clinical benefit (response plus stable disease) in 50-60% of patients for approximately 12-24 months 1.

Traditional cytotoxic chemotherapy like doxorubicin has minimal efficacy and is generally not recommended 1. This is critical because older approaches should be abandoned in favor of targeted therapy.

When to Initiate Systemic Therapy

Systemic therapy should be considered specifically for:

• Clinically progressive disease (documented growth on serial imaging)
• Symptomatic metastases (pain, functional impairment, or organ compromise)

Active surveillance remains appropriate for slow-growing, low tumor burden disease even if RAI-refractory 3. This is an important caveat—not all RAI-refractory disease requires immediate systemic treatment.

Local Treatment for Bone Metastasis

For the iliac bone lesion specifically, external beam radiation therapy demonstrates a clear dose-response relationship 2. A 2026 study of 280 bone metastases in DTC patients showed:

• High-dose radiation (BED10 ≥ 40) significantly reduced progression (HR 0.50, p=0.003)
• Median progression time: 3.3 years for low-dose vs. not reached for high-dose
• Treatment should exceed BED10 = 40 when suitable 2

This represents the most recent, high-quality evidence specifically addressing bone metastases in this population.

Indications for Local Therapy

Consider radiation therapy for:

• Symptomatic bone lesions (pain control)
• Structural complications (impending fracture, spinal cord compression risk)
• Limited sites of progression during systemic therapy or surveillance
• Oligometastatic disease where local control may delay systemic therapy need

Multimodal Treatment Algorithm

The optimal approach combines systemic and local therapies:

1. If progressive/symptomatic disease with multiple sites: Initiate lenvatinib as first-line systemic therapy 1

2. For the iliac bone lesion specifically: Add external beam radiation (BED10 ≥ 40) for local control 2

3. If oligometastatic or single-site progression: Consider radiation alone with close surveillance before committing to systemic therapy 3

4. If bone metastases present: Initiate antiresorptive therapy (bisphosphonates or denosumab) to prevent skeletal-related events 3

Alternative and Emerging Options

The 2025 Chinese Guidelines acknowledge several alternatives when standard options are unsuitable 4:

• Redifferentiation therapy: BRAF/MEK inhibitors (dabrafenib + trametinib) may restore iodine uptake in select cases, achieving partial response in 38% at 6 months 4
• Peptide receptor radionuclide therapy (PRRT) and radioligand therapy targeting FAP/PSMA remain exploratory 4
• Immunotherapy: Limited benefit except in rare TMB-high cases; pembrolizumab + lenvatinib showed 62% ORR but lacks randomized data proving superiority over lenvatinib alone 4

Critical Pitfalls to Avoid

1. Don't use cytotoxic chemotherapy as first-line treatment—it's ineffective in metastatic DTC 1

2. Don't assume all RAI-refractory disease needs immediate systemic therapy—assess progression rate and symptoms first 3

3. Don't undertreat bone metastases with radiation—doses below BED10 = 40 show inferior local control 2

4. Don't overlook molecular profiling—though no mutations predicted local control in the radiation study 2, targetable alterations (RET fusions, NTRK fusions) would change systemic therapy selection to selective inhibitors over lenvatinib 3

5. Don't forget bone-protective therapy—antiresorptive agents are indicated for bone metastases regardless of other treatments 3

Treatment Sequencing

For progressive disease: Lenvatinib first-line → cabozantinib second-line (recently approved for VEGFR-targeted MKI progression) 3

For surgical candidates: If the iliac lesion is potentially resectable and causing significant symptoms, perioperative systemic therapy combined with surgery can be considered, though this requires clinical trial validation 4

The evidence strongly supports a dual approach prioritizing both systemic control with lenvatinib and aggressive local treatment of the bone lesion with high-dose radiation when the disease is progressive or symptomatic.